Immuron Limited IMRN
0.93 USD +0.05 (+5.37%)
At closeNov 11, 2026, 4:00 PM EST
0.96 +0.03 +3.39%
After hours · Nov 11, 4:00 PM ET
0.90 Day range 0.9549
0.677 52-week range 1.99
- YTD
- +21.55%
- 1 year
- -42.75%
News
benzinga.com Immuron Retains LifeSci Capital As Its Exclusive Financial Advisor To Assist In Evaluating Strategic Initiatives To Maximize Shareholder Value Strategic initiatives under consideration may include, but are not limited to mergers, acquisitions, licensing, or other strategic transactions. There can be no assurance that the strategic process…
globenewswire.com Immuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Initiatives MELBOURNE, Australia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) today announced that it has engaged LifeSci Capital to serve as its exclusive financial advisor to…
globenewswire.com Immuron continued quarterly sales growth Sales Highlights (unaudited): Global Q1 sales AUD$2.2 million up 9% on prior comparative period (pcp) Q1 sales up 5% on prior quarter Australia Q1 sales AUD$1.8 million up 14% on prior comparative…
globenewswire.com Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference MELBOURNE, Australia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the…- benzinga.com Immuron Announces Publication Of Data From Its Phase 2 Clinical Trial Of Once-Daily Oral Travelan In 'Scientific Reports'; Statistically Significant 50% Reduction In ETEC Challenge-Related Adverse Events Versus Placebo Immuron Limited ((ASX: IMC, NASDAQ:IMRN) today announced that data from its Phase 2 clinical trial of once-daily oral Travelan® has been published in the Nature Journal, Scientific Reports.A copy of…
globenewswire.com Travelan® Phase 2 Study Results Published MELBOURNE, Australia, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) today announced that data from its Phase 2 clinical trial of once-daily oral Travelan® has been…
defenseworld.net Immuron (NASDAQ:IMRN) Sees Significant Increase in Short Interest Immuron (NASDAQ: IMRN - Get Free Report) was the target of a significant increase in short interest in September. As of September 15th, there was short interest totaling 115,685 shares, an increase…
defenseworld.net Immuron (NASDAQ:IMRN) Shares Down 2.5% – What’s Next? Shares of Immuron (NASDAQ: IMRN - Get Free Report) dropped 2.5% on Friday. The company traded as low as $1.16 and last traded at $1.16. 43,882 shares changed hands during mid-day trading, a decline…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Immuron (NASDAQ:IMRN) shares moved upwards by 48.2% to $1.65 during Friday's regular session. The market value of their outstanding shares is at $8.9 million. bioAffinity Technologies…
benzinga.com Gold Falls Over 1%; American Outdoor Brands Shares Jump After Q1 Results U.S. stocks fell as August jobs beat estimates; oil, gold and silver declined. Immuron, Quanex and AOUT surged, while GWRE, LULU and PATH dropped.
benzinga.com Dow Falls Over 100 Points; US Economy Adds 162,000 Jobs In August U.S. stocks mixed as Dow and S&P fell despite strong August job gains; tech rose, energy slid, and oil, gold and silver declined.
benzinga.com Immuron Stock Surges Friday: What's Driving the Action? Shares of Immuron Limited (NASDAQ:IMRN) are surging Friday morning following news that the Australian biopharmaceutical company signed an exclusive agreement to launch PROIBS gut health product in…
benzinga.com Immuron Stock Surges Friday: What's Driving the Action? Immuron shares are surging Friday after it announced an exclusive deal with Calmino group AB to launch PROIBS gut health product in the U.S.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Immuron (NASDAQ:IMRN) stock increased by 64.9% to $1.83 during Friday's pre-market session. The company's market cap stands at $8.9 million. Akanda (NASDAQ:AKAN) shares increased by 27.52% to…
benzinga.com Market-Moving News for September 4th PL: 13% | PL stock has given up its prior gain. Planet Labs shares were trading higher after the company reported better-than-expected Q2 sales results. IMRN: 58% | Immuron Announces Exclusive U.S.…
globenewswire.com Immuron to launch PROIBS® in the United States MELBOURNE, Australia, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to announce that it has executed an exclusive distribution agreement for PROIBS® in the…
defenseworld.net Immuron (NASDAQ:IMRN) and Applied Therapeutics (NASDAQ:APLT) Financial Analysis Applied Therapeutics (NASDAQ: APLT - Get Free Report) and Immuron (NASDAQ: IMRN - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two…
globenewswire.com Presenting on Emerging Growth Conference 95 Day 2 on August 20; Register to live stream MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth. com a leading independent small cap media portal announces the schedule of the 95th Emerging Growth Conference on August 19 and 20, 2026. The…
globenewswire.com Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year MELBOURNE, Australia, July 16, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce…
benzinga.com Immuron Hires Pullan To Find Partner For Gut Infection Drug, Seeks Strategic Partner For FDA-Cleared IMM-529 Trial Immuron Limited ((ASX: IMC, NASDAQ:IMRN) is pleased to announce that it has engaged Pullan Consulting to provide business development services to assist in securing a strategic partnership for…
globenewswire.com Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy Key Points Immuron Engages Pullan Consulting to Advance IMM-529 Partnering Strategy Immuron is seeking a partner to support clinical development through regulatory approval and commercialization…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
accessnewswire.com Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00 NEW YORK CITY, NY / ACCESS Newswire / April 22, 2026 / Emerging Growth Research today released a Flash Report on Immuron (Nasdaq:IMRN), maintaining its Buy-Extended rating while increasing its…
globenewswire.com Immuron Double Digit 3Q Sales Growth Sales Highlights (unaudited): Global Q3 sales AUD$1.5 million up 16% on prior comparative period (pcp) YTD Mar 2026 sales AUD$5.7 million up 7% on prior comparative period (pcp) Australia Q3 sales…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
accessnewswire.com Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target NEW YORK CITY, NEW YORK / ACCESS Newswire / March 5, 2026 / Emerging Growth Research today released a Flash Research Update on Immuron Limited (Nasdaq:IMRN), maintaining its Buy-Extended rating and…
benzinga.com Immuron H1 EPS $(0.01), Same YoY, Sales $4.184M Up From $3.994M YoY Immuron (NASDAQ:IMRN) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year. The company reported $4.184 million in sales this quarter. This is a 4.76…
accessnewswire.com Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target NEW YORK CITY, NY / ACCESS Newswire / January 22, 2026 / Emerging Growth Research today released a Flash Research Update on Immuron Limited (Nasdaq:IMRN), maintaining its Buy-Extended rating and…- benzinga.com Reported Monday, Immuron Reports Continued Sales Growth With H1 Global Sales Of AUD$4.2M, Up 5%, Driven By Travelan And ProIBS Launch Sales Highlights (unaudited):GlobalH1 sales AUD$4.2 million up 5% on prior comparative period (pcp)Q2 sales AUD$2.2 million up 11% on prior quarterAustralia H1 sales AUD$3.3 million up 13% on prior…
globenewswire.com Immuron Reports Continued Sales Growth Sales Highlights (unaudited): Global H1 sales AUD$4.2 million up 5% on prior comparative period (pcp) Q2 sales AUD$2.2 million up 11% on prior quarter Australia H1 sales AUD$3.3 million up 13% on…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session 
benzinga.com Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com Why Braze Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket 
benzinga.com Why UiPath Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Immuron Announces A New Research Agreement With The Naval Medical Research Command And The Walter Reed Army Institute Of Research, Funded By U.S. Department Of Defense Subaward As previously announced on August 16, 2024, the Naval Medical Research Command and the Walter Reed Army Institute of Research, in collaboration with Immuron, are progressing the development of novel…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
globenewswire.com Immuron IMM-529 IND approved by FDA Key Points Immuron receives U.S. Food and Drug administration (FDA) approval for IMM-529 Investigational New Drug (IND) application and clinical study may proceed FDA assigned an IND number (032095)…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
newsfilecorp.com Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target New York, New York--(Newsfile Corp. - October 17, 2025) - Emerging Growth Research today announced the initiation of coverage on Immuron Limited (Nasdaq: IMRN) with a Buy-Extended rating and a…
globenewswire.com Immuron Q1 FY26 YoY growth Sales Highlights (unaudited): Global • Q1 sales AUD$2.0 million up 34% on prior comparative period (pcp) Australia • Q1 sales AUD$1.6 million up 52% on pcp Canada • Q1 sales AUD$0.0 million down 92%…
benzinga.com Why Interactive Brokers Group Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session